#Blazing New Trails in T-Cell Therapy Atara Biotherapeutics Resubmission of Tab-cel BLA Amidst Record Revenue Surge,...

Developers Resubmit BLA for Tab-Cel in EBV+ Lymphoproliferative Disease

The FDA lifted a clinical hold on a new drug application for tabelecleucel as a treatment for EBV-positive lymphoproliferative disease in May 2025.

Tabelecleucel Advances in EBV+ PTLD With Phase 3 Trial and FDA Resubmission

Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA approval on the horizon.

#Blazing New Trails in T-Cell Therapy Atara Biotherapeutics Resubmission of Tab-cel BLA Amidst Record Revenue Surge,...

'Advancing Innovation: Atara Biotherapeutics Resubmits BLA for Groundbreaking T-Cell Therapy, Amidst Impressive Growth' Atara Biotherapeutics, Inc. (Nasdaq: ATRA) is making waves in the biotech industry with an impressive blend of scientific innovation and business acumen. The Thousand Oaks-based leader in T-cell immunotherapy recently announced significant progress in its mission to provide transformative therapies for patients suffering from c…